Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (NYSE American: CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancers throughout the body. Its platform uses the radioactive isotope lead-212 (212Pb), attached to targeting molecules designed to bind cancer cells, and lead-203 (203Pb)… From the company’s description.
Over the twelve months to Jun 30, 2026, Perspective Therapeutics, Inc. reported revenue of $0.41M, down 66.9% from a year earlier, and a net loss of $116.43M. Operations used $93.07M in cash. In fiscal 2025, it reported revenue of $0.88M, down 39.2% from fiscal 2024, and a net loss of $103.12M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Perspective Therapeutics, Inc. does
In the company’s own words
Perspective Therapeutics, Inc. (NYSE American: CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancers throughout the body. Its platform uses the radioactive isotope lead-212 (212Pb), attached to targeting molecules designed to bind cancer cells, and lead-203 (203Pb) imaging agents that use the same targeting molecules to help identify tumors and guide treatment. The company’s three lead programs are in Phase 1/2a imaging and therapy trials: VMT-α-NET targets SSTR2-expressing neuroendocrine tumors, VMT01 targets MC1R-expressing melanoma, and PSV359 targets fibroblast activation protein in solid tumors. It is also developing regional facilities to prepare clinical drug candidates and support potential commercial supply, using proprietary 212Pb generator technology. Perspective retains global development and commercialization rights to its product candidates, subject to an exclusive option granted to a Lantheus affiliate to negotiate a license for VMT-α-NET. The company’s technology platform was developed over more than 15 years at the University of Iowa.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 728387
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Perspective Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Perspective Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Perspective Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Perspective Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Perspective Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”